SUPRAMOLECULARTHERANOSTIC PLATFORMS GOES GREEN

Year 2019, Volume: 20 , 164 - 169, 16.12.2019

Ruken Esra Demirdöğen , Derya Kılıç , Fatih Emen , Ali Karaçolak , Muhammad Ali , Emine Kutlu , Tuncay Yeşilkaynak , Gokturk Avsar

https://doi.org/10.18038/estubtda.656356

Abstract

World Health Organization projected the number of deaths due to cancer alone to be ~13.1 million by 2030. To a certain extent conventional chemotherapy has been successful, but poor bioavailability, high-dose requirements, adverse side effects, low therapeutic indices, development of multiple drug resistance, and non-specific targeting have been severe limitations to its success. These limitations can be overcome via “theranostics” as it is precision medicine providing simultaneous diagnosis, targeted treatment and monitoring. Here the major actor is the drug –the therapeutic compound. It is importance to develop new green chemistries and technologies to produce supramolecular nanomedicines by employing appropriate inorganic and organic structures as theranostic platforms. SrMoO4:Eu3+- MCM-41-ɣ-Fe2O3 composite was synthesized and characterized via FT-IR and XRD techniques. XRD pattern of SrMoO4:Eu3+- MCM-41-ɣ-Fe2O3 composite shows the presence of SrMoO4 (PDF card No: 01-075-4312), γ-Fe2O3 (PDF card no: 00-013-0458) and amorphous SiO2 structures. The drug loading was investigated via TG systems. The amount of Ibuprofen loaded in the drug loaded SrMoO4:Eu3+-MCM-41-ɣ-Fe2O3 microstructures, which were calculated from the TG curves, was found to be 14%. The release behavior of ibuprofen from SrMoO4:Eu3+- MCM-41-ɣ-Fe2O3-Ibu was investigated in the PBS solution at pH = 7.4 and at 37 oC for 66 h. In the first 8 h., Ibuprofen is released on the surface absorbed and clinging to weak interactions. After than, Slow release of ibuprofen attached to the pores was observed.

Keywords

Theranostics, mesoporous ɣ-Fe2O3

Supporting Institution

TÜBİTAK and Burdur Mehmet Akif Ersoy University coordinator of scientific research

Project Number

Project number of 116Z402, project number of 2017-YL-0472.

References

• [1] S. Jeelani, R. Jagat Reddy, T. Maheswaran, G. Asokan, A. Dany, B. Anand, Theranostics: A treasured tailor for tomorrow, J. Pharm. Bioallied Sci. 6 (2014) 6.
• [2] H.-B. Cheng, Y.-M. Zhang, Y. Liu, J. Yoon, Turn-On Supramolecular Host-Guest Nanosystems as Theranostics for Cancer, Chem. 5 (2019) 553–574..
• [3] P. Szell, S. Zablotny, D.B.-N. communications, 2019, Halogen bonding as a supramolecular dynamics catalyst, nature.com.
• [4] A. Pöthig, A. Casini, Recent Developments of Supramolecular Metal-based Structures for Applications in Cancer Therapy and Imaging., Theranostics. 9 (2019) 3150–3169.
• [5] V.E. Vorobeva, N.E. Domracheva, M.S. Gruzdev, A.V. Pyataev, Optical properties and photoinduced superparamagnetism of γ-Fe2O3 nanoparticles formed in dendrimer, Mater. Sci. Semicond. Process. 38 (2015) 336–341.
• [6] C. He, T. Sasaki, Y. Shimizu, N. Koshizaki, Synthesis of ZnO nanoparticles using nanosecond pulsed laser ablation in aqueous media and their self-assembly towards spindle-like ZnO aggregates, Appl. Surf. Sci. 254 (2008) 2196–2202.
• [7] E. Darezereshki, M. Ranjbar, F. Bakhtiari, One-step synthesis of maghemite (γ-Fe2O3) nano-particles by wet chemical method, J. Alloys Compd. 502 (2010) 257–260.
• [8] M. Jarlbring, L. Gunneriusson, B. Hussmann, W. Forsling, Surface complex characteristics of synthetic maghemite and hematite in aqueous suspensions, J. Colloid Interface Sci. 285 (2005) 212–217.
• [9] S. Dash, P. Murthy, L. Nath, P.C.-A.P. Pharm, 2010, Kinetic modeling on drug release from controlled drug delivery systems, ptf.content-manager.pl.